Fotemustine and recurrent glioblastoma: Possible new opportunities for an old drug

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 863-866

  Addeo, Raffaele ^a   De Santi, M Serena ^b   Del Prete, Salvatore ^a   Caraglia, Michele ^c  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b Umberto I Hospital   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CEDIRANIB; CISPLATIN; DACARBAZINE; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLATINUM; PROCARBAZINE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER PATIENT; CYTOREDUCTIVE SURGERY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLIOBLASTOMA; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; METHYLATION; NEOPLASM RECURRENCE, LOCAL; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; ORGANOPHOSPHORUS COMPOUNDS; PROMOTER REGIONS, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69049099853     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1086-6     Document Type: Editorial

References (21)

1. M Huncharek J Muscat 1998 Treatment of recurrent high grade astrocytoma: results of a systematic review of 1415 patients Anticancer Res 18 2B 1303 1311
2. R Stupp WP Mason MJ van den Bent et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 987 996
3. R Stupp ME Hegi WP Mason et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 5 459 466
4. Stupp R, Hegi M E, van den Bent et al. (2006) Changing paradigms: an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180
5. JJ Vredenburgh A Desjardins JE Herndon II et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 30 4722 4729
6. A Fabi G Metro M Russillo A Vidiri et al. 2009 Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation BMC Cancer 9 101
7. Brandes AA, Tosoni A, Franceschi E et al. (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol (Epub ahead of print)
8. MG Fabrini G Silvano I Lolli F Perrone A Marsella V Scotti L Cionini 2009 A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma J Neurooncol 92 1 79 86
9. S Scoccianti B Detti A Sardaro et al. 2008 Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience Anticancer Drugs 19 6 613 620
10. JL Fischel P Formento MC Etienne J Gioanni M Frenay P DeloVre JP Bizzari G Milano 1990 In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea Cancer Chemother Pharmacol 25 337 341
11. JF Parkinson HR Wheeler A Clarkson et al. 2008 Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma J Neurooncol 87 1 71 78
12. B Fazeny-Dörner M Veitl C Wenzel et al. 2003 Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme Br J Cancer 88 4 496 501
13. A Silvani E Lamperti P Gaviani et al. 2008 Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients J Neurooncol 87 2 143 151
14. TN Kreisl L Kim K Moore et al. 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 5 740 745
15. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Cancer Genome Atlas Research Network. Nature 455(7216):1061-1068
16. B Mukherjee B McEllin CV Camacho et al. 2009 EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma Cancer Res 69 10 4252 4259
17. DW Parsons S Jones X Zhang et al. 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 1807 1812
18. H Yan DW Parsons G Jin et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 8 765 773
19. S Zhao Y Lin W Xu et al. 2009 Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha Science 324 5924 192 194
20. JJ Raizer LE Abrey P Wen et al. 2004 A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant glioma not on EIAEDs J Clin Oncol 22 107s
21. M Frenay C Lebrun M Lonjon et al. 2000 Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas Eur J Cancer 36 8 1026 1031